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ABSTRACT
CONTEXT AND OBJECTIVE: Randomized clinical trials have shown that the new oral anticoagulants have 
at least similar impact regarding reduction of thromboembolic events, compared with warfarin, with simi-
lar or improved safety profiles. There is little data on real costs within clinical practice. Our aim here was 
to perform economic analysis on these strategies from the perspective of Brazilian society and the public 
healthcare system. 
DESIGN AND SETTING: Cost-minimization analysis; anticoagulation clinic of Hospital Municipal Odilon 
Behrens, Belo Horizonte, MG, Brazil.
METHODS: Patients at the anticoagulation clinic were recruited between August and October 2011, with 
minimum follow-up of four weeks. Operational and non-operational costs were calculated and corrected 
to 2015. 
RESULTS: This study included 633 patients (59% women) of median age 62 years (interquartile range 
 49-73). The mean length of follow-up was 64 ± 28 days. The average cost per patient per month was 
$ 54.26 (US dollars). Direct costs accounted for 32.5% of the total cost. Of these, 69.5% were related to 
healthcare professionals. With regards to indirect costs, 52.4% were related to absence from work and 
47.6% to transportation. Apixaban, dabigatran and rivaroxaban were being sold to Brazilian public institu-
tions, on average, for $ 49.87, $ 51.40 and $ 52.16 per patient per month, respectively, which was lower 
than the costs relating to warfarin treatment. 
CONCLUSION: In the Brazilian context, from the perspective of society and the public healthcare system, 
the cumulative costs per patient using warfarin with follow-up in anticoagulation clinics is currently higher 
than the strategy of prescribing the new oral anticoagulants.
RESUMO
CONTEXTO E OBJETIVO: Estudos clínicos randomizados demonstraram que novos anticoagulantes orais 
têm pelo menos impacto semelhante em reduzir eventos tromboembólicos quando comparados à var-
farina, com perfil de segurança similar ou superior. Há pouca evidência acerca de custos reais na prática 
clínica. Nosso objetivo é realizar análise econômica dessas estratégias, na perspectiva do sistema de saúde 
pública e da sociedade brasileiros.
TIPO DE ESTUDO E LOCAL: Análise de custo-minimização; Clínica de Anticoagulação do Hospital Muni-
cipal Odilon Behrens, Belo Horizonte, MG, Brasil.
MÉTODOS: Os pacientes da clínica de anticoagulação foram recrutados de agosto a outubro de 2011, 
com tempo mínimo de acompanhamento de quatro semanas. Custos operacionais e não operacionais 
foram computados e corrigidos para 2015.
RESULTADOS: Este estudo incluiu 633 pacientes, com idade mediana de 62 (intervalo interquartil 49-73) 
anos, sendo 59% mulheres. O tempo médio de acompanhamento foi de 64 ± 28 dias. O custo médio por 
paciente por mês foi de $ 54.26 (dólares). Custos diretos foram responsáveis por 32,5% do custo total. 
Destes, 69,5% foram relacionados aos profissionais de saúde. Em relação aos custos indiretos, 52,4% es-
tavam relacionados ao absenteísmo ao trabalho e 47,6% ao transporte. Apixaban, dabigatran e rivaroxa-
ban são vendidos a órgãos públicos brasileiros, respectivamente, a um preço médio mensal de $ 49.87, 
$ 51.40 e $ 52.26 por paciente por mês, valores inferiores aos custos relacionados ao tratamento com 
varfarina.
CONCLUSÃO: No contexto brasileiro, na perspectiva do sistema de saúde pública e da sociedade, os 
custos cumulativos por paciente em uso de varfarina acompanhados em clínica de anticoagulação são 
atualmente superiores à estratégia de prescrever novos anticoagulantes orais.
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INTRODUCTION 
Atrial fibrillation is the most common sustained arrhythmia in 
clinical practice. It is associated with increased risk of stroke, 
systemic embolism, heart failure and mortality.1,2 Occurrences 
of stroke relating to atrial fibrillation are usually more severe, 
with a more extensive affected area, greater mortality and 
poorer functional outcome, in comparison with patients with-
out atrial fibrillation.3 The current treatment for atrial fibrilla-
tion focuses on estimating the risk of cardioembolic events, in 
order to assess the need for anticoagulation, rate control, rhythm 
control in some symptomatic individuals and aggressive modi-
fication of cardiovascular risk.1 Use of anticoagulant therapy is 
effective in reducing the incidence of stroke, systemic embolism 
and mortality.4
A recent study that enrolled approximately 300,000 
Brazilian primary care patients showed a prevalence of atrial 
fibrillation similar to that observed in developed countries, 
with a very low proportion of patients taking anticoagulants.5 
The possible explanations for this underutilization are the 
lack of doctors in primary care with experience of managing 
patients with atrial fibrillation and making risk assessments 
on cardioembolic events; fear of the risk of bleeding compli-
cations such as intracranial hemorrhage; and limitations asso-
ciated with the use of vitamin K inhibitors, such as the need 
for frequent dose control and adjustment in accordance with 
the prothrombin time and the international normalized ratio 
(INR), as well as the interactions of these inhibitors with drugs 
and food. Anticoagulation clinics are specialized clinics with 
multidisciplinary composition, which have a dual mission: to 
ensure patient education and information in accordance with a 
structured program that is adapted to each case; and to promote 
anticoagulation control.6,7
Clinical trials have shown that the new oral anticoagulants, 
also known as target-specific anticoagulants, have at least similar 
impact on the reduction of thromboembolic events, compared 
with warfarin, with better safety profiles.8-12 Important additional 
advantages include convenience, since there is no need to moni-
tor the INR and thus no further consultations except for the rou-
tine medical follow-up; and fewer interactions: they present lack 
of susceptibility to dietary interactions and reduced susceptibility 
to drug interactions.8-12
There are few data comparing the cost of these drugs with 
actual costs of patients in clinical practice in Brazil. 
OBJECTIVE
The objective of this study was to perform an economic analy-
sis comparing new oral anticoagulants versus warfarin, from the 
perspectives of Brazilian society and the public healthcare sys-
tem, using real data from an anticoagulation clinic.
METHODS
This was a cost-minimization analysis, using data from a cohort 
of patients of an anticoagulation clinic of Hospital Municipal 
Odilon Behrens, a public hospital in Belo Horizonte. This study 
was approved by the Research Ethics Committee of Hospital 
Municipal Odilon Behrens, and was conducted in accordance 
with the Helsinki Declaration. All patients provided written 
informed consent for their participation in the study.
Patients and setting
All patients registered at this anticoagulation clinic between 
August and October 2011 were recruited for this study. The ser-
vice provided by this clinic operates exclusively through the 
Brazilian public healthcare system (Sistema Único de Saúde, 
SUS), and its clientele consists mostly of patients of low socio-
economic status and low educational level.13
This anticoagulation clinic was established in 2001. Patients 
from the emergency department and hospital inpatient units 
with indications for oral anticoagulation are referred to this clinic 
for follow-up. On the day of the consultation, patients arrive at 
the hospital earlier, for blood collection for measurement of pro-
thrombin time, which is expressed as the international normal-
ized ratio (INR), using the calibration standardized by the World 
Health Organization (WHO) in 1982.14 
While awaiting the test result and consultation, they partic-
ipate in group educational activities, where they receive guid-
ance on indications, risks and benefits of anticoagulation, and 
on interactions with food and diet. These educational activi-
ties are additional to the personalized educational activities that 
take place during the consultation. Although group educational 
activities are not formally recommended through guidelines for 
patient care in cases of anticoagulant use, this strategy is used in 
this anticoagulation clinic, because it has been shown to improve 
the time in therapeutic range (TTR).15 
At the time of this study, the anticoagulation clinic was oper-
ating in four shifts per week, with the participation of one physi-
cian with overall responsibility, two or three residents, one phar-
macist and one nurse. In addition, the clinic also had a secretary, 
who organized the records and service.
At each visit, the INR was assessed, the factors that interfere 
with anticoagulation control were identified and any dose adjust-
ments needed were made, in accordance with a protocol based on 
guidelines for patient care in cases of anticoagulant use.14 Patient 
counseling was reinforced and the next visit was scheduled. 
The interval between consultations varied from less than one week 
to up to four weeks, depending on the INR result and whether 
there were any hemorrhagic complications, in accordance with 
the guidelines at that time.14 When the INR was within the thera-
peutic range, the next visit was scheduled for one week later and, 
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successively, periods of one week were added to this interval, as 
long as the INR was still within the therapeutic range, up to four 
weeks. Thus, the consultation was exclusively for the purpose of 
anticoagulation control and there was no action towards underly-
ing disease control or comorbidities, which were at the discretion 
of the attending physician (primary care physician, internal medi-
cine physician, cardiologist, hematologist, etc.).
Data collection and follow-up
Upon enrollment, patients were interviewed using a standard-
ized questionnaire, and their records were reviewed, in order 
to obtain clinical, demographic and cost data: age, anticoag-
ulation indication, risk factors and comorbidities, disability, 
occupation, salary, means of transportation to the anticoagula-
tion clinic, home address, need to attend the clinic with a com-
panion, companion’s occupation and salary. The categories of 
employment status used were: employee (defined as a person 
working for an employer, person or entity, receiving in return a 
cash compensation, including domestic workers),16 self-employed 
(defined as a person who was the owner of his business),16 
unpaid worker or unemployed.
All patients were followed up for a minimum period of four 
weeks (maximum interval between the consultations, in accor-
dance with the protocol), with assessment of INR tests, warfarin 
dosage, thromboembolic or hemorrhagic complications and hos-
pitalizations. The data-gathering for this study did not affect the 
frequency of consultations or warfarin dosage, which were both 
at the attending physician’s discretion.
The quality of anticoagulation control was assessed by calcu-
lating the length of TTR, using the linear interpolation method 
of Rosendaal.17 The CHADS2-Vasc score, which is a clinical pre-
diction rule for estimating the risk of stroke in patients with non-
valvular atrial fibrillation, was used too.
Assessment of costs
Cost assessment was performed by accounting for all the expenses 
involved in anticoagulation for the patients of the  cohort. 
The  costs were classified into two categories: direct and indi-
rect (Table 1). Direct costs included operating costs relating to 
maintenance of the anticoagulation clinic: salaries of profes-
sionals working at the clinic (according to the hours devoted 
to this activity), cost of INR examination and cost of the drug 
(warfarin), according to the dose used. Indirect costs were those 
that were unrelated to the operation of the clinic, and included: 
patient transportation costs to the clinic, companion’s transpor-
tation expenses (in the case of patients who attended the consul-
tation with a companion) and opportunity cost.
In order to calculate the transportation cost, the means of 
transport used by each patient to attend the consultations was 
taken into account. For those who needed public transportation, 
we used the price of the bus ticket and the number of tickets used 
per day. For patients who used their own car, the distance from 
their home to the anticoagulation clinic was calculated (using 
Google Maps, available at www.google.com.br/maps) and, con-
sidering an average fuel consumption of 10 km per liter of gaso-
line and the average cost of gasoline (checked at the website www.
mercadomineiro.com.br), the transportation cost was calculated. 
For patients who used the city’s patient transportation service, 
funded by the city government, the cost of fuel was taken into 
consideration, using the same calculation as above, and the cost 
of the driver’s salary. The cost of car rental was not calculated, 
since cities generally have their own cars for providing this type 
of service. Patients who needed taxi services were asked about 
their exact expenditure for their journey. To calculate the driver’s 
earnings per hour, data from the National Household Sampling 
Survey were used (Pesquisa Nacional de Amostra de Domicílios, 
PNAD).16,18 Through PNAD, we obtained the amount of the aver-
age hourly wage, which formed the reference value for the param-
eter. The range of salary was constructed by taking into consid-
eration a range of one to four minimum wages as the monthly 
remuneration and assuming a working week of 40 hours.18
The opportunity cost refers to the amount of income from 
work that the individual failed to earn,18 or the cost to the indi-
vidual of absence from work, through attending the consultation 
at the anticoagulation clinic. 
The costs were calculated as the prices of July 2013, and were 
inflated in accordance with the Consumer Price Index (Índice de 
Preços ao Consumidor Amplo, IPCA) and converted to US dol-
lars (USD) on August 19, 2015 (1 USD = R$ 3.486). In this study, 
all costs are expressed in US dollars.
Cost-minimization analysis
Since apixaban, dabigatran and rivaroxaban have been shown to 
be not inferior to warfarin in randomized clinical trials among 
patients with atrial fibrillation and patients with venous throm-
boembolism,6,7,9,19,20 the present study used cost-minimization 
analysis. This method is a type of cost-effectiveness analysis that 
only compares two or more medical intervention costs, since the 
health outcomes resulting from the medical interventions com-
pared are similar.21
In Brazil, apixaban, dabigatran and rivaroxaban are autho-
rized by the National Health Surveillance Agency (Agência 
Nacional de Vigilância Sanitária, Anvisa) for use in patients 
with atrial fibrillation for prevention of cardioembolic events. 
Only dabigatran and rivaroxaban are authorized for use among 
patients with deep venous thrombosis and/or pulmonary embo-
lism. To calculate the average cost of apixaban, dabigatran and 
rivaroxaban, we used the average price data for the period from 
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January 1 to August 19, 2015, from the federal government’s drug 
purchasing website, which lists the prices of drugs for public 
institutions.22 Edoxaban was not included, because it has not yet 
been approved by Anvisa for use in Brazil.
RESULTS
During the study period, 645 patients were registered in the 
anticoagulation clinic. Of these, 12 refused to participate. 
Thus, this study included 633 patients with a median age of 
62 years (interquartile range 49-73), among whom 53.9% were 
elderly patients (≥ 60 years) and 59% were women. Table 2 
illustrates the indications for anticoagulation among the 
patients included. 
Among the patients with non-valvular atrial fibrillation 
(n = 246), the CHADS2-Vase score was 1 for 1.2% of them, 2 for 
8.9%, 3 for 20.3%, 4 for 27.2%, 5 for 22.0%, 6 for 15.4%, 7 for 3.3% 
and 8 for 0.8%. In two cases, we could not obtain all the informa-
tion needed to calculate the CHADS2-Vasc score.
The mean follow-up period was 64 ± 28 days. The average 
proportion of the time in therapeutic range was 69.2% ± 25.0% 
(median 71.2%, interquartile range 52.8 to 92.4%), and 65.7% of 
the patients were within the therapeutic range for greater than 
or equal to 60% of the time. During the follow-up, 2.7% of the 
patients required administration of vitamin K and 1.6% had an 
episode of minor bleeding (hematoma, epistaxis, gingival bleed-
ing or increased menstrual flow, without the need for hospitaliza-
tion and/or transfusion of blood components). Two patients had 
gastrointestinal bleeding and one patient had hematuria. One 
patient (75 years old, male) presented an embolic event (isch-
emic stroke) during the follow-up, with INR at admission of 1.94.
Table 1. Description of the costs included in the cost-minimization analysis
Direct costs






Calculation of the cost of each professional who was working in the clinic, 
with labor charges proportional to the number of hours worked per week 
in the activity
Data collection in the human 
resources sector of the hospital
Cost of INR exams
Calculation of all the costs involved in the INR examination including 
material for blood collection, laboratory staff and printing costs.
Data collection at the laboratory 




Annualized cost of the drug (warfarin), according to dose per patient 
monitoring period. Furthermore, the annualized cost of vitamin K was 
calculated when it was necessary during the follow-up. 
Data collection
Indirect costs
Category Variable Description Source
Transportation 
cost (cost 
for the city’s 
government)
Driver’s salary per 
hour




Number of hours spent by the driver on patient transportation and 
waiting for appointments in anticoagulation clinic
Calculation of the average 
duration of transportation from 
Google, and average waiting time 
for the consultation
Number of people 
transported
Number of people transported to be attended at the anticoagulation clinic 
in Belo Horizonte
NA
Gasoline price Gasoline price for patients’ transportation Website “Mercado Mineiro”
Number of km 
per liter
Number of kilometers per liter of gasoline
The average consumtion rate of 
10 km/liter was used
Transportation 
cost (cost for the 
individual)
Ticket price Cost of the ticket for the bus or metro x number of tickets per day Data collected from the individual
Gasoline price Gasoline price for patients’ transportation Website “Mercado Mineiro”
Number of km 
per liter
Number of kilometers per liter of gasoline
The average consumption rate of 




Number of hours spent on shuttling back and forth, blood collection, 




Ratio between the individual’s income for that job and the number of 
hours worked





Number of hours spent by the companion for each consultation, including 
hours spent on shuttling back and forth, blood collection, waiting for 




Ratio between the individual’s income for that job and the number of 
hours worked
Data collected from the individual
PNAD = Pesquisa Nacional por Amostra de Domicílios; NA = not applicable.
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Table 3 shows the total annualized costs for the 633 patients 
included. The average cost per patient per month was $ 54.26. 
Direct costs accounted for 32.5% of the total cost. Of these, 69.5% 
were costs relating to healthcare professionals, 21.8% to INR tests 
and 8.7% to warfarin. With regard to indirect costs (67.5% of the 
total), 52.4% were related to absenteeism from work and 47.6% to 
transportation to the clinic. 
According to data from the federal government’s drug pur-
chasing website, the average prices of apixaban, dabigatran 
and rivaroxaban for the public institutions from January 1st 
to August 19th, 2015,20 respectively, were $ 49.87, $ 51.40 and 
$ 52.16 per month, respectively (Table 4). Figure 1 provides a 
graphical representation of a projection of this difference for 
the Brazilian population. 
Sensitivity analysis
Table 5 illustrates the sensitivity analysis on the cost of anticoag-
ulation using warfarin among elderly versus non-elderly patients, 
according to origin (Belo Horizonte versus other cities), distance 
from the home to the anticoagulation clinic (greater or less than 
20 kilometers and greater or less than 30 kilometers) and indica-
tion (atrial fibrillation versus other indications).
Table 2. Characteristics of patients included (n = 633) 
Characteristics n (%)
Indication for anticoagulation*
Atrial fibrillation 359 (58.8)
Atrial fibrillation with valvulopathy 58 (9.2)
Atrial fibrillation without valvulopathy 301 (47.6) 
Deep vein thrombosis/pulmonary embolism 229 (36.2)
Valvulopathy without atrial fibrillation 30 (4.7)
Chagas disease 28 (4.4)
Chagas disease and atrial fibrillation 19 (3.0)
Left ventricle thrombus 25 (3.9)
Arterial thrombosis 22 (3.5)
Chronic pulmonary hypertension 14 (2.2)
Mesenteric thrombosis 11 (1.7)
Intracranial thrombosis 9 (1.4)






Prosthetic orthopedic devices 1





Government funding due to disease 49 (7.7)
Pensioner 25 (3.9)






Government funding due to disease 1
Pensioner 2
Transportation
On foot 20 (3.2)
Bus 401 (63.3)†
Bus with companion 112 (17.7)
Bus and taxi 12 (1.9)
Own car 112 (17.7)
City’s car 17 (2.7)
Taxi 64 (10.1)
Missing data 7 (1.1)
*Patients could have more than one indication for anticoagulation; 
†Out of the 412 patients who used a bus, 63.6% used two buses, 
29.6% used four buses and 4.4% used six buses per day to attend the 
consultation at the anticoagulation clinic.
Table 3. Annualized direct and indirect costs relating to patients 
at the anticoagulation clinic who were using warfarin (n = 633) 
Direct costs
Costs for the whole 
sample (n = 633)
Average costs 
per patient*
INR examinations† $ 29,161.73 $ 46.07
Clinical staff $ 93,065.74 $ 147.02
Warfarin $ 11,615.18 $ 18.35
Vitamin K $ 14.76 $ 0.02
Indirect costs
Work absenteeism $ 145,772.69 $ 230.29
Transportation cost $ 132,549.63 $ 209.40
Total $ 412,179.97 $ 651,15
All costs are in US dollars. INR = international normalized ratio. 
*The costs over the same period for a patient using the new 
oral anticoagulants would be: $ 598.44 for apixaban, $ 616.80 for 
dabigatran and $ 625.92 for rivaroxaban; †When the data from the 
study follow up is annualized, each patient would undergo 28 INR 
examinations on average.










Apixaban 5 or 2.5 mg 3 $ 0.82 $ 49.87
Dabigatran 110 mg 5 $ 0.81 $ 49.24
Dabigatran 150 mg 2 $ 0.93 $ 56.78
Dabigatran (average price) 7 $ 0.84 $ 51.40
Rivaroxaban 20 mg 5 $ 1.64 $ 50.11
Rivaroxaban 15 mg 6 $ 1.77 $ 53.86
Rivaroxaban (average price) 11 $ 1.71 $ 52.16
Source: federal government’s drug purchasing website, from 
purchases made between January 1 and August 19, 2015.20 Prices are 
in US dollars. Number of purchases = number of purchases of each 
dosage of each oral anticoagulant registered in the website, from 
the purchases made between January 1 and August 19, 2015.
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DISCUSSION
Population ageing and increasing prevalence of chronic diseases, 
including hypertension and diabetes, which are factors that raise 
the risk of stroke among patients with atrial fibrillation, in addi-
tion to the higher prevalence of atrial fibrillation in the popu-
lation,24 point towards growth in the numbers of patients with 
indications for anticoagulation. In clinical practice in Brazil, 
only a small proportion of patients receive anticoagulant ther-
apy and this requires a solution.5 International guidelines recom-
mend atrial fibrillation screening among patients greater than 
or equal to 65 years of age.25 However, within the Brazilian con-
text, patients with recognized atrial fibrillation have not been 
treated with the recommended therapy for stroke prevention. 
Therefore,  we witness patients being admitted to emergency 
departments presenting the disastrous consequences of strokes, 
which are generally more extensive and therefore associated with 
greater morbidity and mortality than those in patients without 
atrial fibrillation.3,26
The oral anticoagulant therapy currently available in the 
public healthcare system in Brazil is warfarin. It is recom-
mended that the care for patients using oral anticoagulant ther-
apy with warfarin should be provided in anticoagulation clinics,14 
because these have been shown to be more effective in control-
ling these patients’ coagulation in terms of efficacy and safety. 
However, given the numbers of patients with indications for anti-
coagulation, creation of the required number of clinics to attend 
the Brazilian population is not feasible. Without these clinics, the 
decision to indicate anticoagulation and monitoring of patients is 
generally at the discretion of primary care physicians, who often 
do not have specific training for this and have limited access to 
continuing education.27,28 Thus, they feel insecure with regard 
to making such decisions and do not have enough time to pro-
vide the number of consultations that anticoagulation control 
requires.14 Additionally, control undertaken at primary care cen-
ters may produce results that are inferior to those at anticoagu-
lation clinics,23 especially considering that performing the blood 
analysis work in different laboratories with interference from 
preanalytical factors and/or without adequate standardization 
of thromboplastin, may lead to problems in measuring INR lev-
els.14 Consequently, this can generate the need for more consulta-
tions and might increase the risk of complications, thereby fur-
ther increasing the cost.
The present study shows that in the context of Brazilian 
healthcare, after calculating all the costs involved in control-
ling anticoagulation at an anticoagulation clinic among patients 
using  warfarin, this strategy has a higher cost than the sale 
price of the new oral anticoagulants to the public institutions. 
These  results are extremely important, considering the urgent 
need to act more effectively in primary and secondary preven-
tion of cardioembolic stroke among patients with atrial fibrilla-
tion within the Brazilian context.5 
The costs for consultations relating to the new oral antico-
agulants were not calculated, since these drugs do not require 
further consultations, other than the usual controls among these 
patients. For both warfarin and the new oral anticoagulants, the 
patient needs to undergo clinical follow-up with the referral phy-
sician, since the anticoagulation clinic only assesses the oral anti-
coagulant therapy.
It is important to note that the strategy of using the new oral anti-
coagulants is not appropriate for all patients with indications for oral 
anticoagulation, since there is lack of evidence regarding the impact 
of the new oral anticoagulants for some conditions, for example, 
among patients with rheumatic valve disease and atrial fibrillation, 
Table 5. Sensitivity analysis on average monthly cost per 
patient using warfarin, at the anticoagulation clinic
Criteria Costs
Age
≥ 60 years $ 49.78
< 59 years $ 59.54
Origin
Belo Horizonte $ 50.40
Other cities $ 69.80
Distance from home
≥ 20 km $ 63.62
< 20 km $ 51.80
≥ 30 km $ 97.39
< 30 km $ 50.90
Indication
Atrial fibrillation $ 51.03
Other indications $ 57.35
























Figure 1. Graphical representation of average monthly cost 
of the strategy of using warfarin, at a public anticoagulation 
clinic, versus using apixaban, dabigatran and rivaroxaban, from 
data available on the federal government’s drug purchasing 
website, projected for the Brazilian population. Considering 
a population of 200 million inhabitants (according to the 
Instituto Brasileiro de Geografia e Estatística, at www.ibge.
gov.br) and an estimated prevalence of atrial fibrillation of 1%, 
around 2 million patients need to make use of anticoagulants. 
ORIGINAL ARTICLE | Marcolino MS, Polanczyk CA, Bovendorp ACC, Marques NS, Silva LA, Turquia CPB, Ribeiro AL
328     Sao Paulo Med J. 2016; 134(4):322-9
prosthetic heart valves, Chagas cardiomyopathy and thrombus in 
the left ventricle. Some patient profiles have been excluded from 
clinical trials, such as cases of advanced kidney failure or liver failure; 
or have been underrepresented, such as cases of extremes of weight. 
The sensitivity analysis showed that for some patient profiles, the 
strategy of using the new oral anticoagulants seems to be even more 
economically attractive. For example, among non-elderly patients, 
there is a higher cost relating to absenteeism from work than among 
elderly patients; and among patients living in cities other than where 
the clinic is located, or living at least 20 kilometers from the clinic, 
for whom the cost relating to transportation becomes more signifi-
cant, thus making anticoagulation with warfarin a more expensive 
strategy. When comparing patients using anticoagulants because of 
atrial fibrillation with patients with other indications, the costs of 
taking warfarin were significantly lower among patients with atrial 
fibrillation ($ 51.03 versus $ 57.35). Thus,  for patients with atrial 
fibrillation, the costs of taking warfarin are comparable to the costs 
of taking the new oral anticoagulants.
This study has some limitations. Cost-minimization analy-
sis assumes equivalence between interventions. Clinical trials 
have shown that the new oral anticoagulants are at least as effec-
tive as warfarin, with a better safety profile. Thus, there is poten-
tial for even greater cost reduction with the new oral anticoagu-
lants. Although this was a single-center study, the protocol used in 
this anticoagulation clinic is based on international guidelines for 
patient care with anticoagulant use. Additionally, in these analyses, 
we assumed that control undertaken at anticoagulation clinics is the 
recommended strategy for patients taking warfarin.14 However, con-
trol at anticoagulation clinics is not universally available for patients 
using warfarin, and this comparison may not apply to all settings. 
CONCLUSION
This cost-minimization analysis using real data from clinical prac-
tice found that in the Brazilian context, from the perspectives of 
the public healthcare system and of society, the calculated costs 
relating to warfarin use in anticoagulation clinics seem to be cur-
rently higher than those relating to the strategy of using the new 
oral anticoagulants. These data provide support for the discussion 
about incorporating these new drugs for patients within the pub-
lic healthcare system, with the potential to reduce the incidence of 
systemic embolic events and to bring even greater savings from a 
financial point of view and in terms of public health.
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